FOLD vs GERN
Loading...
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a Hold and GERN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FOLD’s FA Score shows that 0 FA rating(s) are green whileGERN’s FA Score has 1 green FA rating(s).
- FOLD’s FA Score: 0 green, 5 red.
- GERN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FOLD’s TA Score shows that 5 TA indicator(s) are bullish.
- FOLD’s TA Score: 5 bullish, 4 bearish.
Price Growth
FOLD (@Biotechnology) experienced а -2.78% price change this week, while GERN (@Biotechnology) price change was -6.62% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.25%. For the same industry, the average monthly price growth was -4.70%, and the average quarterly price growth was +71.47%.
Reported Earning Dates
FOLD is expected to report earnings on Aug 01, 2024.
GERN is expected to report earnings on Aug 01, 2024.
Industries' Descriptions
@Biotechnology (+0.25% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| FOLD | GERN | FOLD / GERN | |
| Capitalization | 3B | 2.26B | 133% |
| EBITDA | N/A | N/A | - |
| Gain YTD | -28.541 | 80.569 | -35% |
| P/E Ratio | N/A | N/A | - |
| Revenue | N/A | N/A | - |
| Total Cash | N/A | N/A | - |
| Total Debt | N/A | N/A | - |
FOLD | GERN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 72 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 97 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 29 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 63 | 36 | |
P/E GROWTH RATING 1..100 | 100 | 75 | |
SEASONALITY SCORE 1..100 | 85 | 23 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FOLD's Valuation (76) in the Biotechnology industry is in the same range as GERN (97). This means that FOLD’s stock grew similarly to GERN’s over the last 12 months.
GERN's Profit vs Risk Rating (29) in the Biotechnology industry is significantly better than the same rating for FOLD (100). This means that GERN’s stock grew significantly faster than FOLD’s over the last 12 months.
GERN's SMR Rating (98) in the Biotechnology industry is in the same range as FOLD (98). This means that GERN’s stock grew similarly to FOLD’s over the last 12 months.
GERN's Price Growth Rating (36) in the Biotechnology industry is in the same range as FOLD (63). This means that GERN’s stock grew similarly to FOLD’s over the last 12 months.
GERN's P/E Growth Rating (75) in the Biotechnology industry is in the same range as FOLD (100). This means that GERN’s stock grew similarly to FOLD’s over the last 12 months.
| FOLD | |
|---|---|
| RSI ODDS (%) | 1 day ago 81% |
| Stochastic ODDS (%) | 1 day ago 67% |
| Momentum ODDS (%) | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 70% |
| TrendWeek ODDS (%) | 1 day ago 79% |
| TrendMonth ODDS (%) | 1 day ago 75% |
| Advances ODDS (%) | 18 days ago 74% |
| Declines ODDS (%) | 4 days ago 75% |
| BollingerBands ODDS (%) | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 79% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SUVQX | 13.49 | 0.02 | +0.15% |
| PGIM Quant Solutions Large-Cap Val R6 | |||
| VSIAX | 80.10 | 0.11 | +0.14% |
| Vanguard Small Cap Value Index Admiral | |||
| GAOZX | 19.82 | -0.01 | -0.05% |
| JPMorgan Global Allocation R6 | |||
| GLNLX | 22.00 | -0.02 | -0.09% |
| MFS Global New Discovery R3 | |||
| HFDRX | 18.72 | -0.05 | -0.27% |
| Hartford Schroders US MidCap Opps R3 | |||